alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Amyloid, tau and blood-test diagnosis

5,209 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)

Highest usefulness score first. Studies without a score come last.

  1. Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 2011-11-28 Disease mechanisms

    Mounting evidence suggests that amyloid beta-induced impairments in synaptic plasticity that is accompanied by cognitive decline and dementia represent key pathogenic steps of Alzheimer's disease.

  2. Distinguishing Alzheimer's disease from other major forms of dementia

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Expert review of neurotherapeutics 2011-11-01 Getting a diagnosis

    Alzheimer's disease (AD) is the most common and most studied cause of dementia.

  3. New advances in NMDA receptor pharmacology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Trends in pharmacological sciences 2011-10-11 Vascular contributions

    N-Methyl-D-aspartate (NMDA) receptors are tetrameric ion channels containing two of four possible GluN2 subunits.

  4. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular bioSystems 2011-03-24 Disease mechanisms

    The incidence of Alzheimer disease (AD) and diabetes mellitus (DM) is increasing at an alarming rate and has become a major public health concern worldwide.

  5. For debate: substituting placebo controls in long-term Alzheimer's prevention trials

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer's research & therapy 2011-03-21 Treatments

    Forecasted outcomes are compared with outcomes observed on candidate drugs, thus replacing a concomitant placebo group.

    Why it matters

    This paper proposes using forecasted outcomes from historical data to partially replace placebo groups in long-term Alzheimer's prevention trials. It suggests this approach may complement randomized placebo-controlled trial designs in future studies with presymptomatic individuals.

  6. Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Brain research reviews 2011-01-26 Disease mechanisms

    Representing the most common cause of dementia, Alzheimer's disease (AD) has dramatically impacted the neurological and economic health of our society.

  7. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2010-11-01 Disease mechanisms

    Despite the progress of the past two decades, the cause of Alzheimer's disease (AD) and effective treatments against it remain elusive.

  8. How does diabetes accelerate Alzheimer disease pathology?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nature reviews. Neurology 2010-09-14 Disease mechanisms

    Diabetes and Alzheimer disease (AD)-two age-related diseases-are both increasing in prevalence, and numerous studies have demonstrated that patients with diabetes have an increased risk of developing AD compared with healthy individuals.

  9. Fractionating verbal episodic memory in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. NeuroImage 2010-09-09 Hippocampus size on brain scans

    However, a more recent work, derived in part from functional neuroimaging studies, has suggested that other brain structures make up a large-scale network that appears to support successful encoding and retrieval of episodic memories.

  10. Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Human brain mapping 2010-09-01 Hippocampus size on brain scans

    The patterns of subfield atrophy in AD and MCI were consistent with patterns of neuronal cell loss/reduced synaptic density described by histopathology.

  11. P3‐429: Response to cholinesterase inhibitor medication at first renewal in a Canadian provincial drug coverage initiative: the British Columbia Alzheimer's Drug Therapy Initiative (BC ADTI) experience

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2010-07-01 Health systems and care delivery

    Uncertainty surrounds cholinesterase inhibitor (ChEIs) effectiveness in mild to moderate Alzheimer Disease (AD).

    Why it matters

    This study described clinical and cognitive responses to cholinesterase inhibitor medication at first renewal among participants in a Canadian drug coverage program for mild to moderate Alzheimer's disease. The authors state that longer-term follow-up is needed to substantiate the findings, so it does not establish any cure or prevention.

  12. White matter pathology isolates the hippocampal formation in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of aging 2010-02-01 Hippocampus size on brain scans

    Prior work has demonstrated that the memory dysfunction of Alzheimer's disease (AD) is accompanied by marked cortical pathology in medial temporal lobe (MTL) gray matter.

  13. The dysregulation of intracellular calcium in Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Cell calcium 2010-01-18 Disease mechanisms

    Alzheimer disease (AD) is the most common neurodegenerative disorder worldwide and is at present, incurable.

  14. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neuropathology and experimental neurology 2010-01-01 Disease mechanisms

    Aging is the most important single risk factor for developing Alzheimer disease.

  15. Are certain lifestyle habits associated with lower Alzheimer's disease risk?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2010-01-01 Prevention trials

    As the number of patients with Alzheimer's disease (AD) is expected to grow, finding ways to prevent and lower the risk of AD becomes a crucial matter.

  16. Alzheimer's disease as homeostatic responses to age-related myelin breakdown

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of aging 2009-09-22 Brain tissue and pathology

    The amyloid hypothesis (AH) of Alzheimer's disease (AD) posits that the fundamental cause of AD is the accumulation of the peptide amyloid beta (Aβ) in the brain.

    Why it matters

    This review discusses the amyloid hypothesis of Alzheimer's disease and notes that it does not account for recent failures of clinical trials to impact dementia even after successfully reducing amyloid-beta deposits. It proposes viewing the disease from a myelin model perspective focusing on age-related myelin breakdown.

  17. Alzheimer's disease amyloid beta-protein and synaptic function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuromolecular medicine 2009-09-16 Disease mechanisms

    Alzheimer's disease (AD) is characterized neuropathologically by the deposition of different forms of amyloid beta-protein (A beta) including variable amounts of soluble species that correlate with severity of dementia.

  18. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 2009-05-01 Disease mechanisms

    Mitochondria play critical roles in neuronal function and almost all aspects of mitochondrial function are altered in Alzheimer neurons.

  19. Management of agitation and aggression associated with Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Nature reviews. Neurology 2009-05-01 Vascular contributions

    Agitation and aggression are frequently occurring and distressing behavioral and psychological symptoms of dementia (BPSD).

  20. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurobiology of aging 2009-04-22 Mild cognitive impairment

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder with characteristic neuropathological changes of the brain.

    Why it matters

    This study measured 16 plasma signaling proteins in people with Alzheimer's disease, mild cognitive impairment, depression, and healthy subjects. It found increased concentrations of 5 of these proteins in mild cognitive impairment and Alzheimer's disease patients, with sensitivity of 65-75% and specificity of 52-63%.

  21. Amygdala volume marks the acute state in the early course of depression

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biological psychiatry 2008-11-22 Hippocampus size on brain scans

    A state related increase of amygdala volume can be detected early in the course of MDD.

  22. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Psychopharmacology 2008-10-14 Prevention trials

    The use of positive modulators of PLA2 (especially of cPLA2 and iPLA2) or supplementation with dietary lipid compounds (e.g., arachidonic acid) in combination with cognitive training could be a valuable therapeutic strategy for cognitive enhancement in early-stage AD.

  23. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current Alzheimer research 2008-10-01 Disease mechanisms

    There is significant evidence to suggest that a damaged or dysfunctional blood-brain barrier (BBB) may contribute to the pathogenesis of Alzheimer's disease (AD) lesions.

  24. New therapeutic targets in the neurovascular pathway in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2008-07-01 Disease mechanisms

    Recent findings indicate that neurovascular dysfunction is an integral part of Alzheimer's disease (AD).

  25. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current pharmaceutical design 2008-01-01 Disease mechanisms

    Alzheimer's disease (AD) is the most common cause of dementia in developed countries.

From across this topic

10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics